Biotechnology investment in Singapore
As the pharmaceutical industry shifts its emphasis to biologics, Singapore is also keeping pace to build its biopharmaceutical
base. "Having established a reputation as one of the world's most competitive and trusted sites for producing small-molecule-based
active pharmaceutical ingredients and final dosage forms, Singapore is now aggressively pursuing biologics manufacturing investments,
especially since biologics is anticipated to be a key growth driver for the global industry," say Yeoh. "We are quickly building
up a critical mass of biologics manufacturing investments and expect to maintain this momentum as we attract more companies
to set up such manufacturing facilities there." He points to five major biologics manufacturing investments (Lonza, GSK Biologicals, Genentech, and Novartis) that total more than US$1.5 billion.
Yeoh points out the first phase of Singapore's BMS initiative, which was from 2000-2005, focused on putting key building blocks
by establishing core capabilities in biomedical research and introducing human and industrial capital. "For the next phase
(2006-2010), we are building on this foundation and strengthening our capabilities in translational and clinical research
to bring discoveries from the bench to the bedside and the marketplace and ultimately improve human healthcare," says Yeoh.
That effort involves further expansion of its industry R&D base and an increase in the number of companies undertaking the
discovery and development of new drugs and medical devices in Singapore.
For more on this topic, see:
Manufacturing Investment in Puerto Rico
Pharmaceutical and Biopharmaceutical Manufacturing Advances in Ireland
|
